Sarepta Therapeutics: Bears on the Run!

From Stocks To Watch Today
January 10, 2017 - 11:19am

The bears have been in control ever since Sarepta Therapeutics (SRPT) received approval for its Duchenne muscular dystrophy treatment from the FDA. Now they're running for cover after Sarepta released its presentation for the JPMorgan Healthcare Conference. Now shares are up more than 10\%, and it's not hard to see why. Sarepta said that it had generated $5.4 million from sales of its DMD treatment--which appears to be higher than the Street had been expecting. It also said that 250 genetically verified patients had begun the process required to begin treatment--and get it paid for by insurer



Continue reading this article »